MODERN POSSIBILITIES OF MEDICAL TREATMENT OF OVERACTIVE BLADDER IN WOMEN
https://doi.org/10.21518/2079-701X-2017-2-122-127
Abstract
Overactive bladder (OAB) is a serious urination disorder which affects at least 17% of the population above 40 years old, of which 56% are women and 44% are men. M-cholinoblockers are the first line therapy and the main treatment for OAB. However, their side effects, along with low efficacy, force women to stop taking the drugs. Activation of beta-3-adrenergic receptors is known toreduce the tone of detrusor muscle in the bladder. This resulted in the invention of mirabegron (Mirabegron, Betmiga, Astellas Pharma Europe, Netherlands), the first drug of a new pharmacologic group (beta-3 adrenergic agonists) for the treatment of OAB. A selective beta-3 agonist, mirabegron has no side effects such as dry mouth, increased intraocular pressure or constipation. Numerous clinical studies demonstrated a reduction in the number of episodes of urinary incontinence and frequent urination in the mirabegron group compared to the placebo group.
About the Authors
I. A. Apolikhina
Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare of the Russian Federation;
First Moscow State Medical University, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
MD,
Moscow
A. S. Chochueva
Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare of the Russian Federation
Russian Federation
Moscow
Russian Federation
Moscow
A. S. Saidova
Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
PhD in Medicine,
Moscow
E. A. Gorbunova
Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare of the Russian Federation
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Abrams P. The standartisation of terminology of lower urinary tract function. Neurourol. and Urodyn, 2002, 21: 167-178.
2. Гаджиева Ж.К. Нарушения мочеиспускания: руководство. Под ред. Ю.Г. Аляева. М.: ГЭОТАР-Медиа, 2010. 176 с.
3. Пушкарь Д.Ю. Гиперактивный мочевой пузырь у женщин. М.: МЕД пресс-информ, 2003. 160 с.
4. Джавад-Заде М.Д., Державин В.М., Вишневский Е.Л. Нейрогенные дисфункции мочевого пузыря. М.: Медицина, 1989.
5. Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A populationbased prevalence study. BJU Int, 2001, 87: 760–6.
6. Вишневский Е.Л., Пушкарь Д.Ю., Лоран О.Б., Данилов В.В., Вишневский А.Е. Урофлоуметрия. М., 2004: 263, 176–183, 183–208.
7. Moller LA, Lose G, Jorgensen T. Risk factors lower urinary tract symptoms in women 40 to 60 years of age. Obstet. Gynecol., 2000, 96: 446–51.
8. Cruz F. Vanilloid receptor and detrusor instability. Neurology and Urodynamics, 2009: 29–34.
9. Takeda M, Obara K, Mizusawa T et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther., 1999, 288, 3: 1367–1373.
10. Takeda H, Yamazaki Y, Akahane M et al. Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J. Pharmacol. Exp. Ther., 2000, 293(3): 939–945.
11. Otsuka A, Shinbo H, Matsumoto R et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 377(4–6): 473–481.
12. Liu Hsin-Tzu, Chancellor MB, Kuo H-Ch. Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection. European urology, 2009, 56: 700-707.
13. Liu Hsin-Tzu, Chancellor MB, Kuo H-Ch. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU international, 2009, 103(12): 1668-72.
14. Lesch KP, Merschdorf U. Impulsivity, aggression, and serotonin: a molecular psychobiological perspective. Behav Sci Law, 2000, 18: 581-604.
15. Zifa E, Fillion G. 5-Hydroxytryptamine receptors. Pharmacol. Rev., 1992, 44: 401-458.
16. Michel M, Ochodnicky P, Homma Y and Igawa Y. β-adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther, 2011, 131: 40–49.
17. Stenberg F, Heimer G, Ulmsten U. The prevalence of urogenital symptoms in postmenopausal women. Maturitas, 1995, 22(Suppl): 17–20.
18. Кулаков В.И., Аполихина И.А. Недержание мочи у женщин: новые возможности в диагностике и лечении. Гинекология, 2004, 4(3): 103–5.
19. Groat WC. Afferent nerve regulation of bladder function in health and disease. Handb. Exp. Pharmacol., 2009, 194: 91-138.
20. Abrams P and Wein. Overactive bladder and its treatments. Urology, 2000, 55(sup.).
21. Mukerji G et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. I. Urol., 2006, 176(1): 367-373.
22. Mulsant B, Pollock B, Kirshner M, Shen C, Dodge H and Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry, 2003, 60: 198–203.
23. Milsom I, Abrams P, Cardozo L, Roberts R, Thuroff J, Wein A. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int., 2001, 87: 760–766.
24. Wein AJ Rackley R.R. Overactive bladder: a better understanding of pathophysiology, diagnosis and management J Urol, 2006, 175(3 Pt 2): S5–10;
25. Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther., 1999, 288: 1367–1373.
26. Sacco E, Tienforti D, D’Addessi A, Pinto F, Racioppi M, Totaro A, D’Agostino D, Marangi F, Bassi P. Social, economic, and health utility considerations in the treatment of overactive bladder. J. Urol., 2010, 2: 11–24.
27. Gruneberger A. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. Br. J. Obstetr. Gynaecol., 1984, 91: 275–278.
28. FDA Summary of safety and efficacy as basis for Advisory Committee briefing document for mirabegron, 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Reproductive HealthDrugsAdvisoryCommittee/UCM298284.pdf
29. Chapple C, Amarenco G, Lopez Aramburu M, Everaert K, Liehne J, Lucas M et al. A proof-ofconcept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn, 2013a, 32: 1116–1122.
30. Chapple C, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele J, Bosman B et al. (2013b) A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J, 24: 1447–1458.
31. Nitti V, Herschorn S, Auerbach S et al. The selective [beta] 3-adrenoreceptor agonist mirabegron is effective and well tolerated in patients with overactive bladder syndrome. J. Urol., 2011, 185(4): e783–e784.
32. Khullar V, Amarenco G, Angulo JC et al. Efficacy and tolerability of mirabegron, a β(3)- adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur. Urol., 2013, 63(2): 283–295.
33. Chapple C, Kaplan S, Mitcheson H et al. Randomised, double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)adrenoceptor agonist, in overactive bladder (OAB). Eur. Urol., 2013, 62(2): 296–305.
34. Rossanese M, Novara G, Challacombe B, Iannetti A, Dasgupta P and Ficarra V. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a beta(3)-adrenoceptor agonist (mirabegron) for overactive bladder (OAB). BJU Int, 2015, 115: 32–40.
35. Rosa G, Ferrero S, Nitti V, Wagg A, Saleem T and Chapple C. Cardiovascular safety of beta3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol, 2016, 69: 311–323.
36. Baber RJ, Panay N, Fenton A и рабочая группа IMS, 2016.
Review
For citations:
Apolikhina IA, Chochueva AS, Saidova AS, Gorbunova EA. MODERN POSSIBILITIES OF MEDICAL TREATMENT OF OVERACTIVE BLADDER IN WOMEN. Meditsinskiy sovet = Medical Council. 2017;(2):122-127. (In Russ.) https://doi.org/10.21518/2079-701X-2017-2-122-127
Views:
756
Email this article 